Ad26.RSV.preF-based vaccine

BIOLOGICAL4 trials

Sponsors

Janssen Vaccines & Prevention B.V.

Conditions

Influenza, Human PreventionRespiratory Syncytial Virus Infection PreventionRespiratory Syncytial Virus PreventionRespiratory Syncytial Viruses Prevention

Phase 3

A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection

CompletedNCT05070546

Janssen Vaccines & Prevention B.V.Respiratory Syncytial Virus Infection Prevention

Start: 2021-09-29End: 2022-08-12Updated: 2025-05-25

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

CompletedNCT05071313

Janssen Vaccines & Prevention B.V.Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention

Start: 2021-10-04End: 2022-10-11Updated: 2025-05-25

A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old

CompletedNCT05083585

Janssen Vaccines & Prevention B.V.Respiratory Syncytial Virus Prevention

Start: 2021-10-08End: 2022-09-22Updated: 2025-05-25

A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years

CompletedNCT05101486

Janssen Vaccines & Prevention B.V.Respiratory Syncytial Virus Prevention

Start: 2021-11-01End: 2022-09-20Updated: 2025-05-25

Related Papers

Climate footprint of industry-sponsored in-human clinical trials: life cycle assessments of clinical trials spanning multiple phases and disease areas

BMJ Open2025-02-014 citations

Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial.

2024-11-124 citations